share_log

OmniAb (NASDAQ:OABI) Coverage Initiated at Truist Financial

OmniAb (NASDAQ:OABI) Coverage Initiated at Truist Financial

OmniAB（纳斯达克股票代码：OABI）的报道由Truist Financ
Financial News Live ·  2022/12/22 02:51

Equities research analysts at Truist Financial initiated coverage on shares of OmniAb (NASDAQ:OABI – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. Truist Financial's target price would indicate a potential upside of 159.07% from the stock's current price.

据The Fly报道，Truist Financial的股票研究分析师在周二发布的一份报告中发起了对OmniAb(纳斯达克：OABI-GET评级)股票的报道。该经纪公司为该股设定了“买入”评级和10.00美元的目标价。Truist Financial的目标价显示，该股较当前股价有159.07%的潜在上涨空间。

Several other equities research analysts have also recently issued reports on OABI. Credit Suisse Group started coverage on shares of OmniAb in a research note on Friday, December 16th. They set an "outperform" rating and a $13.00 price target on the stock. SVB Leerink started coverage on shares of OmniAb in a research report on Tuesday, November 29th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Stifel Nicolaus started coverage on shares of OmniAb in a research report on Monday, November 28th. They issued a "buy" rating and a $12.00 target price on the stock.

其他几位股票研究分析师最近也发布了关于OABI的报告。瑞士信贷集团在12月16日星期五的一份研究报告中开始报道OmniAb的股票。他们为该股设定了“跑赢大盘”的评级和13.00美元的目标价。SVB Leerink在11月29日星期二的一份研究报告中开始报道OmniAb的股票。他们对该股的评级为“跑赢大盘”，目标价为6.00美元。最后，Stifel Nicolaus在11月28日星期一的一份研究报告中开始报道OmniAb的股票。他们对该股的评级为“买入”，目标价为12美元。

Get
到达
OmniAb
OmniAb
alerts:
警报：

OmniAb Trading Up 17.0 %

OmniAb交易上涨17.0%

OmniAb stock opened at $3.86 on Tuesday. OmniAb has a 12-month low of $1.91 and a 12-month high of $10.50.

OmniAb的股票周二开盘报3.86美元。OmniAb的12个月低点为1.91美元，12个月高位为10.50美元。

Insider Activity

内幕活动

In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
在其他新闻方面，首席执行官马修·W·福尔在11月30日星期三的一笔交易中收购了30万股该公司股票。这些股票是以每股3.39美元的平均价格购买的，总交易额为1,017,000.00美元。收购完成后，首席执行官现在直接拥有1,705,350股公司股票，价值约5,781,136.50美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在
this hyperlink
此超链接
. In other news, CEO Matthew W. Foehr acquired 300,000 shares of the company's stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $3.39 per share, for a total transaction of $1,017,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,705,350 shares of the company's stock, valued at approximately $5,781,136.50. The transaction was disclosed in a filing with the SEC, which is available at
。在其他新闻方面，首席执行官马修·W·福尔在11月30日星期三的一笔交易中收购了30万股该公司股票。这些股票是以每股3.39美元的平均价格购买的，总交易额为1,017,000.00美元。收购完成后，首席执行官现在直接拥有1,705,350股公司股票，价值约5,781,136.50美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在
this hyperlink
此超链接
. Also, CEO Matthew W. Foehr purchased 150,000 shares of the company's stock in a transaction that occurred on Monday, December 12th. The stock was bought at an average price of $3.77 per share, with a total value of $565,500.00. Following the purchase, the chief executive officer now owns 1,838,084 shares of the company's stock, valued at approximately $6,929,576.68. The disclosure for this purchase can be found
。此外，首席执行官马修·W·福尔在12月12日(星期一)的一次交易中购买了15万股公司股票。这只股票是以每股3.77美元的平均价格购买的，总价值为565,500.00美元。收购后，这位首席执行官现在拥有1,838,084股公司股票，价值约6,929,576.68美元。关于这次购买的披露可以找到
here
这里
. Insiders have bought 482,250 shares of company stock worth $1,694,038 over the last 90 days.
。在过去的90天里，内部人士购买了482,250股公司股票，价值1,694,038美元。

About OmniAb

关于OmniAb.

(Get Rating)

(获取评级)

OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.

OmniAbInc.是一家生物技术公司，在美国提供治疗性抗体发现技术。该公司的发现平台为行业合作伙伴提供了访问各种抗体谱系和筛选技术的机会，以实现下一代疗法的发现。它的OmniAbPlatform是专有转基因动物的生物智能，包括Omni大鼠、OmniChicken和OmniMouse，这些动物已经经过基因改造，产生具有人类序列的抗体，以促进人类候选治疗的开发。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on OmniAb (OABI)
  • Lucid Motors Faces a Reality That May Cloud a Bullish Perception
  • Institutions Put Bottom In Rite Aid Shares
  • Here's Why You Should Steer Clear of the FedEx Bounce
  • Why Did Viking Therapeutics Stock Skyrocket
  • NIKE, Inc Swooshes Higher On Results And Outlook
  • 免费获取StockNews.com关于OmniAb的研究报告(OABI)
  • Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
  • 机构将Rite Aid的股票跌至谷底
  • 这就是为什么你应该避开联邦快递的反弹
  • 维京治疗公司股票为何暴涨
  • 耐克公司业绩和前景走高

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.

接受OmniAbDaily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对OmniAb及相关公司的评级的每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发